CDH1 and carcinoma: Significant shifts towards a more mesenchymal phenotype (as indicated by an increase in the proportion of the mesenchymal marker vimentin to epithelial marker E-cadherin [36]) after talazoparib treatment were observed in the paired biopsies of 2 of the 4 carcinoma patients evaluable for the primary PD endpoint, as well as in the progression biopsy of patient #8 (Fig. 4).